Barinthus Biotherapeutics has shared its most significant recent data from the ongoing Phase IIb HBV003 clinical trial for chronic hepatitis B. The newest data was cut off on 30 September (for lab ...

Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in hepatitis B. The company reported data from the 24-week point of ...

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer. Being tested in the first ...

31, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B - Global Clinical Trials Review ... country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent ...

In the latest results from the 457-patient B-Clear study, published in the New England Journal of Medicine, bepirovirsen at a dose of 300 mg per week over 24 weeks resulted in sustained hepatitis ...

Our Phase 2 trial of hydronidone for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis showed that adding hydronidone to entecavir resulted in significant reversal of liver ...

The investigational combo of Vir’s monoclonal antibody tobevibart and Alnylam-discovered siRNA elebsiran was measured in a phase 2 trial for patients with chronic hepatitis B (CHB). Participants ...

The estimated prevalence rate is 3-5% for Hepatitis B and 7-10% for Hepatitis C. The first phase of the programme was launched in August 2005 with a Rs2.59 billion budget and the aim of reducing ...